Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Hepsera; Belgium: Hepsera; Cyprus: Hepsera; Czech Republic: Hepsera; Denmark: Hepsera; Estonia: Hepsera; Finland: Hepsera; France: Hepsera; Germany: Hepsera; Hungary: Hepsera; Ireland: Hepsera; Italy: Hepsera; Latvia: Hepsera; Luxembourg: Hepsera; Netherlands: Hepsera; Poland: Hepsera; Portugal: Hepsera; Romania: Hepsera; Slovakia: Hepsera; Spain: Hepsera; Sweden: Hepsera; UK: Hepsera.

North America

Canada: Hepsera; USA: Hepsera.

Latin America

Argentina: Biovir, Hepsera, Revervir; Brazil: Hepsera; Mexico: Hepsera.


Japan: Hepsera.

Drug combinations


Adefovir: C~8~H~12~N~5~O~4~P. Mw: 273.19. (1) Phosphonic acid, [[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]-; (2) [[2-(6-Amino-9H-purin-9-yl)ethoxy]methyl]phosphonic acid; (3) 9-[2-(Phosphonomethoxy)ethyl]adenine. CAS-106941-25-7 (1994).

Adefovir Dipivoxil: C~20~H~32~N~5~O~8~P. Mw: 501.47. (1) Propanoic acid, 2,2-dimethyl-, [[[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]phosphinylidene]bis(oxymethylene) ester; (2) [[2-(6-Amino-9H-purin-9-yl)ethoxy]methyl]phosphonic acid, diester with hydroxymethyl pivalate; (3) 9-[2-[[Bis[(pivaloyloxy)methoxy]phosphinyl]methoxy]ethyl]adenine.CAS-142340-99-6 (1996).

Pharmacologic Category

Antiviral Agents; Nucleosides and Nucleotides; Reverse Transcriptase Inhibitors. (ATC-Code: J05AF08).

Mechanism of action

Interferes with hepatitis B virus (HBV) viral RNA-dependent DNA polymerase resulting in inhibition of viral replication.

Therapeutic use

Treatment of chronic hepatitis B virus infection with evidence of active viral replication (based on persistent elevation of ALT/AST or histologic evidence), including patients with lamivudine-resistant hepatitis B.

Pregnancy and lactiation implications

Use in pregnancy only when clearly needed. Not recommended during lactation.

Unlabeled use


Hypersensitivity to adefovir or any component of the formulation.

Warnings and precautions

Lactic acidosis and hepatomegaly with steatosis reported (use with caution in patients with risk factors for liver disease). Acute exacerbation of hepatitis B may occur upon discontinuation (risk may be increased with advanced liver disease or cirrhosis). May cause the emergence of HIV resistance in unrecognized or untreated HIV patients. Use with caution in renal dysfunction/toxicity (may result in nephrotoxicity).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart